Abstract
The government employs innovation subsidies as a key incentive strategy to promote companies to innovate more technically. This study analyses how innovation subsidies influences the quality of corporate innovation. We create an innovation quality index for pharmaceutical corporations using categorizing data from patent applications submitted by pharmaceutical companies. Using data from 180 listed Chinese pharmaceutical companies between 2010 and 2020, this study proposes a panel regression model to assess the influence of government innovation subsidies on innovation quality, as well as the moderating effect of CEOs' academic capital. How well innovations are subsidized is also affected by the heterogeneity of property rights. Innovation subsidy has a greater and more positive impact on non-SOEs. This article demonstrates that CEOs with academic credentials and executives with ties to the pharmaceutical industry have a variety of moderate effects. The research offers novel suggestions for enhancing business creativity and the innovation subsidy programme.